Crossmark Global Holdings Inc. Makes New Investment in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Crossmark Global Holdings Inc. bought a new position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 4,720 shares of the medical device company’s stock, valued at approximately $200,000.

Other large investors have also recently modified their holdings of the company. Assetmark Inc. bought a new stake in Tandem Diabetes Care during the 3rd quarter valued at approximately $29,000. JB Capital LLC lifted its stake in shares of Tandem Diabetes Care by 7.2% in the 3rd quarter. JB Capital LLC now owns 33,729 shares of the medical device company’s stock valued at $1,430,000 after purchasing an additional 2,259 shares during the period. Hanseatic Management Services Inc. boosted its position in shares of Tandem Diabetes Care by 5.4% during the third quarter. Hanseatic Management Services Inc. now owns 13,941 shares of the medical device company’s stock valued at $591,000 after purchasing an additional 710 shares in the last quarter. Stephens Investment Management Group LLC grew its stake in Tandem Diabetes Care by 12.2% in the third quarter. Stephens Investment Management Group LLC now owns 1,274,482 shares of the medical device company’s stock worth $54,051,000 after purchasing an additional 138,263 shares during the period. Finally, abrdn plc bought a new position in Tandem Diabetes Care in the third quarter worth $6,126,000.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Canaccord Genuity Group dropped their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. UBS Group raised shares of Tandem Diabetes Care to a “hold” rating in a research note on Friday, August 2nd. Robert W. Baird decreased their target price on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Barclays boosted their price target on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $55.00 price target (up previously from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and a consensus price target of $54.25.

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $28.76 on Tuesday. The firm has a market cap of $1.89 billion, a PE ratio of -14.51 and a beta of 1.36. Tandem Diabetes Care, Inc. has a 1-year low of $17.33 and a 1-year high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The firm has a fifty day simple moving average of $37.46 and a two-hundred day simple moving average of $41.68.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.08. The company had revenue of $243.97 million for the quarter, compared to the consensus estimate of $224.14 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. Tandem Diabetes Care’s revenue was up 31.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.38) earnings per share. On average, equities analysts anticipate that Tandem Diabetes Care, Inc. will post -1.73 EPS for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.